Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Undertreated Patients.

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon May 31, 2021 4:45pm

215 Views

Post# 33297671

RE:RE:RE:RE:Undertreated Patients.

I believe it was At the time it was not disclosed what the optimization was, but Dr Lilge was presenting on the importance of a personalized treatment dependant on bladder volume and shape and light Dosimetry taking into account individual bladder surface light reflectivity as well as any turbidity in the saline solution and the like.

Johnandrose22 wrote: Thank you, Enriquesuave. Would it be accurate to presume that maximum bladder volume was employed for Phase I patients? I can’t seem to find any data on this.

John

<< Previous

Bullboard Posts

Next >>

Rock Tech notches official permit for German lithium refinery